The FDA has approved Grifols' Xembify, or immune globulin subcutaneous, human-klhw, 20% solution, as a treatment for patients ages 2 and older with primary humoral immunodeficiency. The company plans to launch the drug in the fourth quarter of the year.
Grifols' primary immunodeficiency drug gets FDA nod
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.